Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View

被引:40
作者
Jarczak, Dominik [1 ]
Kluge, Stefan [1 ]
Nierhaus, Axel [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care Med, D-20246 Hamburg, Germany
关键词
immune response; immunoglobulins; sepsis; septic shock; IVIg; IgGAM; NEUTROPHIL EXTRACELLULAR TRAPS; CRITICALLY-ILL PATIENTS; NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; B-CELLS; POLYCLONAL IMMUNOGLOBULIN; COMPLEMENT ACTIVATION; IN-VITRO; PERSONALIZED MEDICINE; DR EXPRESSION;
D O I
10.3390/ijms21155543
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is a life-threatening organ dysfunction, defined by a dysregulated host immune response to infection. During sepsis, the finely tuned system of immunity, inflammation and anti-inflammation is disturbed in a variety of ways. Both pro-inflammatory and anti-inflammatory pathways are upregulated, activation of the coagulation cascade and complement and sepsis-induced lymphopenia occur. Due to the manifold interactions in this network, the use of IgM-enriched intravenous immunoglobulins seems to be a promising therapeutic approach. Unfortunately, there is still a lack of evidence-based data to answer the important questions of appropriate patient populations, optimal timing and dosage of intravenous immunoglobulins. With this review, we aim to provide an overview of the role of immunoglobulins, with emphasis on IgM-enriched formulations, in the therapy of adult patients with sepsis and septic shock.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 133 条
[71]   Reduced circulating B cells and plasma IgM levels are associated with decreased survival in sepsis - A meta-analysis [J].
Krautz, Christian ;
Maier, Sarah L. ;
Brunner, Maximilian ;
Langheinrich, Melanie ;
Giamarellos-Bourboulis, Evangelos J. ;
Gogos, Charalambos ;
Armaganidis, Apostolos ;
Kunath, Frank ;
Gruetzmann, Robert ;
Weber, Georg F. .
JOURNAL OF CRITICAL CARE, 2018, 45 :71-75
[72]   Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock [J].
Kreyrnann, K. Georg ;
de Heer, Geraldine ;
Nierhaus, Axel ;
Kluge, Stefan .
CRITICAL CARE MEDICINE, 2007, 35 (12) :2677-2685
[73]  
Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI [10.1016/S1473-3099(15)00424-7, 10.1016/S1473-3099(20)30232-2]
[74]   A NET outcome [J].
Lu, Thea ;
Kobayashi, Scott D. ;
Quinn, Mark T. ;
DeLeo, Frank R. .
FRONTIERS IN IMMUNOLOGY, 2012, 3
[75]   Special issue: Sepsis Why have clinical trials in sepsis failed? [J].
Marshall, John C. .
TRENDS IN MOLECULAR MEDICINE, 2014, 20 (04) :195-203
[76]   In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations [J].
Menezes, MCS ;
Benard, G ;
Sato, MN ;
Hong, MA ;
Duarte, AJS .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1997, 114 (04) :323-328
[77]  
Mira JC, 2017, CRIT CARE MED, V45, P253, DOI [10.1097/CCM.0000000000002074, 10.1097/ccm.0000000000002074]
[78]   Sepsis: Diagnostic and Therapeutic Challenges [J].
Molnar, Zsolt ;
Giamarellos-Bourboulis, Evangelos J. ;
Kumar, Anand ;
Nierhaus, Axel .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[79]   Early alterations of B cells in patients with septic shock [J].
Monserrat, Jorge ;
de Pablo, Raul ;
Diaz-Martin, David ;
Rodriguez-Zapata, Manuel ;
de la Hera, Antonio ;
Prieto, Alfredo ;
Alvarez-Mon, Melchor .
CRITICAL CARE, 2013, 17 (03)
[80]   Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin) [J].
Nachbaur, D ;
Herold, M ;
Gächter, A ;
Niederwieser, D .
IMMUNOLOGY, 1998, 94 (02) :279-283